Flag of the European Union EU Clinical Trials Register Help

Clinical trials for slovakia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44356   clinical trials with a EudraCT protocol, of which   7382   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,279 result(s) found for: slovakia. Displaying page 9 of 114.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2010-020603-79 Sponsor Protocol Number: AB08004 Start Date*: 2012-12-21
    Sponsor Name:AB Science
    Full Title: A prospective, multicentre, randomized, double-blind, placebo-controlled, 2-parallel groups, phase 2 study to evaluate efficacy and safety of 12 weeks treatment with masitinib versus placebo in pat...
    Medical condition: patients suffering from Acute Ischemic Stroke
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10023027 Ischaemic stroke NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2010-022037-29 Sponsor Protocol Number: AFU-GETUG 20/0310 Start Date*: 2011-01-31
    Sponsor Name:FNCLCC (Fédération Nationale des Centres de Lutte Contre le Cancer)
    Full Title: Phase III randomised trial to evaluate the benefit of adjuvant hormonal treatment with leuprorelin acetate (Eligard® 45 mg) for 24 months after radical prostatectomy in patients with high risk of r...
    Medical condition: PROSTATIC ADENOCARCINOMA WITH HIGH RISK OF RECURRENCE.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10060862 Prostate cancer LLT
    Population Age: Gender: Male
    Trial protocol: FR (Trial now transitioned) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-000205-21 Sponsor Protocol Number: CCJM112X2204 Start Date*: 2018-01-29
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, subject- and investigator-blinded, placebo-controlled, multi-center, multiple dose study to assess the efficacy and safety of CJM112 in patients with inadequately controlled moderate ...
    Medical condition: Inadequately controlled moderate to severe asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) BE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2011-000602-22 Sponsor Protocol Number: B2611002 Start Date*: 2011-06-29
    Sponsor Name:Pfizer Inc
    Full Title: A 12-WEEK, PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-RANGING, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE DAILY PF-04991532 AND SITAGLIPTIN IN ADULT PATIENTS ...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    13.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-000723-32 Sponsor Protocol Number: B2611003 Start Date*: 2011-07-29
    Sponsor Name:Pfizer Inc
    Full Title: A 12-WEEK, PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE DAILY PF-04991532 AND ONCE DAILY SITAGLIPTIN IN ADU...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    13.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-004411-22 Sponsor Protocol Number: CSPP100A2365E2 Start Date*: 2012-03-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, 52 to 104 week extension study to evaluate the long term growth and development of pediatric hypertensive patients 6 – 17 years of age treated previously with aliskiren
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10020772 Hypertension PT
    14.1 10047065 - Vascular disorders 10039834 Secondary hypertension PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-005793-63 Sponsor Protocol Number: CLIK066A2202 Start Date*: 2013-10-30
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, double-blind, double-dummy, parallel-group dose-finding study to evaluate the change in HbA1c after 12 weeks monotherapy with seven doses of LIK066 compared with placebo...
    Medical condition: Type II Diabetes mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) SK (Prematurely Ended) IT (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001660-30 Sponsor Protocol Number: CHL.3/01-2019/M Start Date*: 2020-06-03
    Sponsor Name:Sintetica S.A.
    Full Title: A prospective, observer-masked, randomized clinical trial to investigate and compare the clinical efficacy of chloroprocaine 3% gel and tetracaine 0.5% eye drop as topical anesthetics in phacoemuls...
    Medical condition: cataract surgery
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10063797 Cataract operation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004179-33 Sponsor Protocol Number: I8F-MC-GPGB Start Date*: 2017-06-15
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2 Study of Once-Weekly LY3298176 Compared with Placebo and Dulaglutide in Patients with Type 2 Diabetes Mellitus
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-000767-23 Sponsor Protocol Number: D7990C00003 Start Date*: 2020-11-12
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomized, Parallel, Double-blind, Placebo-controlled, Dose-ranging, Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD8233 Treatment in Participants With Dyslipidemia
    Medical condition: Dyslipidemia, especially: evaluation of low-density lipoprotein cholesterol reduction at steady state at different doses of AZD8233 in order to select a therapeutic dose.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10058108 Dyslipidaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-000925-27 Sponsor Protocol Number: ProF-001_Phase_IIb/III Start Date*: 2019-08-27
    Sponsor Name:Profem GmbH
    Full Title: A phase IIb/III, parallel-arm, randomized, active-controlled, double-blind, double-dummy, study in patients with recurrent vulvovaginal candidiasis to compare the clinical efficacy, safety and tole...
    Medical condition: recurrent vulvovaginal candidiasis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10047784 Vulvovaginal candidiasis PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002067-10 Sponsor Protocol Number: BP41321 Start Date*: 2020-07-27
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A randomized, double-masked, 48-week parallel-group, placebo-controlled, proof-of-concept study to investigate the efficacy and safety of RG7774 in patients with Diabetes Mellitus Type 1 or Type 2 ...
    Medical condition: Diabetic retinopathy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2022-000476-18 Sponsor Protocol Number: SPX-CF-001 Start Date*: 2022-05-24
    Sponsor Name:EnBiotix, Inc.
    Full Title: Tolerability and Safety of Inhaled Colistimethate Sodium Administered Once Daily Compared to Twice Daily Dosing in Adult and Adolescent Subjects with Cystic Fibrosis and Chronic Pseudomonas Aerugin...
    Medical condition: Chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011763 Cystic fibrosis lung PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Ongoing) SK (Prematurely Ended) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000676-38 Sponsor Protocol Number: ISEE2008 Start Date*: 2020-06-17
    Sponsor Name:IVERIC bio, Inc.
    Full Title: A Phase 3 Multicenter, Randomized, Double Masked, Sham-Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients wit...
    Medical condition: geographic atrophy secondary to dry age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10075567 Dry age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) HU (Completed) EE (Completed) LV (Completed) PL (Completed) CZ (Completed) ES (Completed) IT (Completed) SK (Prematurely Ended) BE (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2013-001835-33 Sponsor Protocol Number: CLCZ696B2228 Start Date*: 2013-09-19
    Sponsor Name:Novartis Pharma services AG
    Full Title: A multicenter, randomized, double-blind, parallel group study to assess the safety and tolerability of initiating LCZ696 in heart failure patients comparing two titration regimens.
    Medical condition: Chronic heart failure
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) IT (Completed) SK (Completed) ES (Completed) DE (Completed) FI (Completed) GB (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-001562-42 Sponsor Protocol Number: CSPP100A2370 Start Date*: 2013-12-26
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A randomized, double-blind, parallel group, active-controlled study to compare the systolic blood pressure lowering efficacy of aliskiren, ramipril and a combination of aliskiren and amlodipine, wi...
    Medical condition: essential hypertension
    Disease: Version SOC Term Classification Code Term Level
    16.1 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) SK (Completed) HU (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005432-28 Sponsor Protocol Number: NEUGR-005 Start Date*: 2013-10-15
    Sponsor Name:Teva Pharmaceuticals Industries Ltd.
    Full Title: An open label, randomized, active controlled, dose finding study to evaluate the pharmacodynamics, pharmacokinetics, efficacy and safety of balugrastim at doses of 300 μg/kg and 670 μg/kg in pediat...
    Medical condition: Neutropenia induced by chemotherapy in patients with solid tumors
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10065252 Solid tumor LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Completed) BG (Prematurely Ended) SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004862-16 Sponsor Protocol Number: D5496C00005 Start Date*: 2020-06-03
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 2, Multicentre, Double-Blind, Placebo and Active Control Efficacy and Safety Study to Evaluate Verinurad combined with Allopurinol in Heart Failure with Preserved Ejection Fraction
    Medical condition: Heart Failure Patients with Preserved Ejection Fraction (HFpEF) and hyperuricaemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10076396 Heart failure with preserved ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BG (Completed) PL (Completed) SK (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001074-29 Sponsor Protocol Number: CLOU064A2201E1 Start Date*: 2019-10-10
    Sponsor Name:Novartis Pharma AG
    Full Title: An open-label, multicenter, extension study to evaluate the long-term safety and tolerability of LOU064 in eligible subjects with CSU who have participated in CLOU064A2201
    Medical condition: Chronic Spontaneous Urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) CZ (Completed) SK (Completed) FR (Completed) DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-002529-12 Sponsor Protocol Number: CICL670F2203 Start Date*: 2017-10-19
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A phase II, multicenter, open-label, randomized two-year study to evaluate the efficacy and safety of deferasirox film-coated tablet versus phlebotomy in patients with Hereditary Hemochromatosis
    Medical condition: Hereditary Hemochromatosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000012236 10057874 Hereditary hemochromatosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) SK (Completed) DE (Completed) BE (Completed) RO (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Aug 18 20:48:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA